for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

U.S. Supreme Court rejects J&J appeal over Risperdal drug

WASHINGTON, May 17 (Reuters) - The U.S. Supreme Court rejected a bid by Johnson & Johnson to overturn a $70 million jury verdict against the pharmaceutical company for its failure to warn about risks associated with off-label uses of its antipsychotic drug Risperdal.

The court turned away the company’s appeal of a November 2019 ruling by the Superior Court of Pennsylvania that upheld the verdict in favor of a Tennessee man named Adam Yount, who was prescribed the drug at age 4 in 2003. (Reporting by Lawrence Hurley; Editing by Will Dunham)

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up